Table 1 Demographic and clinical parameters of patients (n = 112)
Characteristics | Patients | |
|---|---|---|
No. | % | |
Age (years) | ||
Mean | 52.72 | |
Range | 32-75 | |
Sex | ||
Female | 40 | 35.70% |
Male | 72 | 64.30% |
Lymph node staging | ||
N0 | 25 | 22.32% |
N1 | 49 | 43.75% |
N2 | 38 | 33.93% |
Tumor stage | ||
Stage IIa | 24 | 21.40% |
Stage IIb | 1 | 0.90% |
Stage IIIa | 3 | 2.70% |
Stage IIIb | 53 | 47% |
Stage IIIc | 31 | 27.60% |
Primary tumor location | ||
Rectum | 61 | 54.46% |
Colon | 38 | 33.93% |
Vascular invasion | ||
Positive | 15 | 13.39% |
Negative | 97 | 86.61% |
Nerve invasion | ||
Positive | 24 | 21.43% |
Negative | 88 | 78.57% |
Chemotherapy regimen | ||
Standard FOLFOX-4 | 20 | 17.80% |
Modified FOLFOX | 15 | 13.40% |
Oral XELOX | 19 | 17% |
Conventional intravenous drip infusion | 58 | 51.70% |
Interval of chemotherapy and surgery | ||
Within 28 days | 36 | 32.14% |
More than 28 days | 76 | 67.86% |
Duration of chemotherapy course | ||
1-6 weeks | 21 | 18.75% |
7-12 weeks | 25 | 22.32% |
13-18 weeks | 58 | 51.80% |
19-24 weeks | 8 | 7.14% |
Tumor differentiation | ||
High | 1 | 0.8% |
High or medium | 2 | 1.7% |
Medium | 64 | 57.1% |
Medium or low | 29 | 25.9% |
Low | 16 | 14.3% |
Follow-up | ||
Median | 36 months | |
Range | 1.2-78 months | |
Relapse | 44 | 39.3% |
Death | 11 | 9.8% |
Disease free survival | ||
Median | 36 months | |
Range | 3-77 months | |